Criticism of the Priority Review Voucher (PRV) program has been directed at the lack of requirements for a developed drug to be novel, and to be made affordable. A growing number of novel treatments with post-marketing access plans in place appear to be addressing critics’ concerns.
Priority Review Vouchers And Access To Drugs Targeting Neglected Diseases
